Efficacy News and Research

RSS

QRxPharma, Paladin execute licensing agreement for MOXDUO

QRxPharma Limited announced today execution of a licensing agreement with Paladin Labs Inc. for the Canadian commercialisation rights to MOXDUO, a patented, immediate release formulation of morphine and oxycodone.

10 Oct 2012

Johns Hopkins joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that Johns Hopkins University School of Medicine in Baltimore, MD has joined the Company's ongoing Phase I/II trial in newly diagnosed elderly patients with acute myeloid leukemia (AML).

9 Oct 2012

New data from Genzyme's AUBAGIO and LEMTRADA clinical trials to be presented at ECTRIMS

Genzyme, a Sanofi company, announced today new data from Genzyme's clinical development programs for AUBAGIO (teriflunomide) and LEMTRADATM (alemtuzumab) will be presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10-13.

9 Oct 2012

Recombinant protein may treat male factor fertility

Male factor infertility resulting in failed oocyte activation from dysfunctional sperm phospholipase C-zeta may be remedied through the use of a recombinant form of the protein, leading to efficient blastocyst formation, say scientists.

8 Oct 2012

FDA task force to examine solutions to improve, speed antibiotic research

"One of the most urgent global public health problems is the increasing capability of bacteria to resist antibiotic drugs," a Washington Post editorial states.

8 Oct 2012

New neuroprotective agent for stroke patients potentially found

Scientists have shown that a drug called NA-1 results in fewer brain lesions in patients who have undergone surgery to repair a brain aneurysm, compared to placebo, and appears to be safe to use, according to an Article published Online First in The Lancet Neurology.

8 Oct 2012

ImaginAb enters into neurodegeneration research collaboration agreement with Lundbeck

ImaginAb, Inc., a clinical-stage company developing in vivo molecular imaging agents based on antibody fragment technology, today announced that it has entered into a collaboration and commercialization agreement with H. Lundbeck A/S.

8 Oct 2012

NCI awards Cellerant SBIR contract to develop Megakaryocyte Progenitor Cell therapy for thrombocytopenia

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase 1 contract and a Phase 2 option from the National Cancer Institute (NCI) valued up to $1,683,503.

8 Oct 2012

Trevena reports completion of TRV027 Phase 2a study in advanced heart failure patients

Trevena, Inc., the leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, today announced that it has successfully completed a Phase 2a study on the hemodynamic effects of TRV027 in patients with advanced heart failure with reduced ejection fraction.

8 Oct 2012

Progenra’s USP7 and USP47 exert non-overlapping anticancer cell effects

Researchers at Progenra, Inc. announce the advanced online publication of the article "Selective Dual Inhibitors of the Cancer-related Deubiquitylating Proteases USP7 and USP47." The new article presents evidence of a therapeutic benefit resulting from dual inhibition of USP7 and a related enzyme, USP47.

8 Oct 2012

Study demonstrates efficacy of genotyping technology in identifying source of clinic infection outbreak

Researchers from East Carolina University used a new technique of genotyping to identify the source of a hematology clinic outbreak of Mycobacterium mucogenicum, a gram-positive, acid-fast bacteria found in tap water. This is the first outbreak of M. mucogenicum in an ambulatory care setting; five other outbreaks have been reported in hospital settings since 1995.

6 Oct 2012

Many breast cancer survivors insufficiently active after leaving supervised programs

More than 40 percent of older breast cancer survivors are insufficiently active after leaving a supervised program. But new research shows that those women who developed behavioral skills such as self-confidence and motivation during their program were far more likely to continue exercising on their own.

6 Oct 2012

Combination pill to treat malaria pre-approved by WHO

"A malaria drug made by India's Cipla has been pre-qualified by the World Health Organization (WHO), an important step towards its roll-out across Asia, where millions of people are infected with the mosquito-borne disease every year," Reuters reports.

6 Oct 2012

DPP-inhibitors reduce cardiovascular events in diabetes patients

Type 2 diabetes patients who are treated with dipeptidyl peptidase-4 inhibitors have a significantly reduced risk for cardiovascular events, particularly myocardial infarction, compared with their peers who take placebo or other drugs, results of a meta-analysis show.

5 Oct 2012

Lighting the way to vascular lesion resolution

Treatment with a new-generation optimized pulsed light device significantly decreases the size and coloration of port wine stains and other vascular cutaneous lesions, show research findings.

5 Oct 2012

Bivalent HPV vaccine has cross-protective effect, but could wane over time

The bivalent vaccine for human papillomavirus types 16 and 18 appears to be more efficacious against outcomes associated with nonvaccine types 31, 33, and 45 than its quadrivalent counterpart, show results of a systematic review and meta-analysis.

5 Oct 2012

RXi receives SBIR grant to enable discovery and preclinical development of sd-rxRNAs

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it was awarded a Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI) of the National Institutes of Health (NIH).

5 Oct 2012

UT Austin chair to receive Founders Award from National Academy of Engineering

The National Academy of Engineering has selected Nicholas Peppas as its 2012 Founders Award recipient in recognition of his pioneering work in the areas of polymer chemistry, bioengineering, pharmaceutical sciences and advanced drug delivery.

5 Oct 2012

Article explores safety and efficacy of aerosol delivery of drugs in ICU patients

Essential medications can be delivered as inhaled drugs to critically ill patients in the Intensive Care Unit (ICU) who require mechanical ventilation to breathe. Aerosol drug delivery is highly complex, however, and if not done properly the medication will not reach the lungs and therapy will be ineffective.

5 Oct 2012

Diabecline wins Drug Store News Best New Product award

Diabecline first aid antibiotic, offered by pharmaCline, has been named the winner of the Drug Store News Best New Product award.

5 Oct 2012

Efficacy News and Research

QRxPharma, Paladin execute licensing agreement for MOXDUO

Johns Hopkins joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

New data from Genzyme's AUBAGIO and LEMTRADA clinical trials to be presented at ECTRIMS

Recombinant protein may treat male factor fertility

FDA task force to examine solutions to improve, speed antibiotic research

New neuroprotective agent for stroke patients potentially found

ImaginAb enters into neurodegeneration research collaboration agreement with Lundbeck

NCI awards Cellerant SBIR contract to develop Megakaryocyte Progenitor Cell therapy for thrombocytopenia

Trevena reports completion of TRV027 Phase 2a study in advanced heart failure patients

Progenra’s USP7 and USP47 exert non-overlapping anticancer cell effects

Study demonstrates efficacy of genotyping technology in identifying source of clinic infection outbreak

Many breast cancer survivors insufficiently active after leaving supervised programs

Combination pill to treat malaria pre-approved by WHO

DPP-inhibitors reduce cardiovascular events in diabetes patients

Lighting the way to vascular lesion resolution

Bivalent HPV vaccine has cross-protective effect, but could wane over time

RXi receives SBIR grant to enable discovery and preclinical development of sd-rxRNAs

UT Austin chair to receive Founders Award from National Academy of Engineering

Article explores safety and efficacy of aerosol delivery of drugs in ICU patients

Diabecline wins Drug Store News Best New Product award

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News